Kezar Life Sciences Inc reports results for the quarter ended in September - Earnings Summary

Kezar Life Sciences

10/11/2022 21:16

* Kezar Life Sciences Inc  KZR.OQ  reported a quarterly
adjusted
loss of 25 cents​​ per share for the quarter ended in September.
The mean expectation of six analysts for the quarter was for a
loss of 27 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kezar Life Sciences Inc's reported EPS for the quarter was
a
loss of 25 cents​.
    * The mean earnings estimate of analysts had risen by
about 6.4%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Kezar Life Sciences Inc shares had fallen by 25.8% this
quarter and lost 61.8% so far this year.
    * The company reported a quarterly loss of $17.85 million.
    * Wall Street's median 12-month price target for Kezar Life
Sciences Inc is $18.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 09:16 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.27          -0.25          Beat
 Jun. 30 2022      -0.27          -0.25          Beat
 Mar. 31 2022      -0.28          -0.26          Beat
 Dec. 31 2021      -0.30          -0.25          Beat